KRAS and neoplasm: In order to assess any relationship between oncogenic activation or loss of tumour suppressor function in the PI3K/AKT and MAPK/ERK signalling pathways, mutations in PIK3CA, PTEN, BRAF and K-RAS, as well as loss of PTEN expression, were tested in relation to each other (Table 5).